Why Viridian Therapeutics, Inc.’s (VRDN) Stock Is Down 5.97%
As of Thursday, October 01, Viridian Therapeutics, Inc.’s VRDN share price has dipped by 5.97%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Stock Evaluator: Viridian Therapeutics, Inc. (VRDN)
Viridian Therapeutics, Inc. VRDN
$18.22
-0.08
-0.44%
October 13, 2026 4:00:00 PM
EST
Volume: 2,124,099
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves’ disease and TED. Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcFn) includes VRDN-006, a highly selective Fc fragment, and VRDN-008, a half-life extended bispecific FcRn inhibitor comprising an GC fragment and an albumin-binding domain designed to prolong IGG suppression. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was incorporated in 2010 and is headquartered in Waltham, Massachusetts.
Commentary & Analysis
Why Viridian Therapeutics, Inc.’s (VRDN) Stock Is Down 5.03%
As of Thursday, September 24, Viridian Therapeutics, Inc.’s VRDN share price has dipped by 5.03%, which has investors questioning if this is right time to buy.Michael Rose
Which Is a Better Investment, Alvotech or Viridian Therapeutics, Inc. Stock?
Learn more about whether Alvotech or Viridian Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Tudor Pop
Which Is a Better Investment, Viridian Therapeutics, Inc. or Xencor, Inc. Stock?
Learn more about whether Viridian Therapeutics, Inc. or Xencor, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Michael Rose
Why Viridian Therapeutics, Inc.’s (VRDN) Stock Is Up 5.07%
As of Monday, August 17, Viridian Therapeutics, Inc.’s VRDN share price has surged by 5.07%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | VRDN | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2,064.2 | $224.8 | 55% |
|
| Shares Out (Mil) | 107.9 | 53.9 | 63% |
|
| Institutional Ownership | 99.9% | 93.1% | 96% |
|
| Float (Mil) | 100.7 | 40.6 | 60% |
|
| Beta | 0.96 | 0.95 | 57% |
|
| Avg Daily Volume (000s) | 2,068 | 632 | 82% |
|
| Price Change (52-week) |
(13.2%) | 47.3% | 40% |
|
| Growth | VRDN | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 130.0% | 12.4% | 99% |
|
| Net Income (5yr) | (25.4%) | (10.2%) | 16% |
|
| EPS (5yr) | 36.1% | 15.7% | 86 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (25.8%) | (15.7%) | 25% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 11 | 12 | 12 | |
| Current EPS | ($0.968) | ($3.884) | ($2.740) | |
| Month Ago EPS | ($0.990) | ($3.949) | ($2.773) | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 0 | 0 | 2 | |
| Three Months Ago EPS | ($0.928) | ($3.799) | ($2.632) | |
| Year/Year Chg | (7.5%) | 16.8% | (73.2%) | |
| Financials | VRDN | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $71 | $37 | 23% |
|
| Net Income (TTM) (Mil) | ($387) | ($44) | 4% |
|
| EPS (TTM) | ($3.458) | ($1.600) | 10% |
|
| Operating Cash Flow (TTM) (Mil) | ($333) | ($33) | 3% |
|
| Net Cash Flow (TTM) (Mil) | $48 | $2 | 70% |
|
| Long-Term Debt (Q1) (Mil) | $244 | $4 | 52% |
|
| Enterprise Value (Q1) (Mil) | $1,986 | $174 | 49% |
|
| Valuation | VRDN | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.66 | 2.17 | 73% |
|
| P/E | na | 19.4 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | VRDN | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (356.5%) | 66.9% | 1% |
|
| Net Margin | (544.1%) | (75.3%) | 1% |
|
| ROA | (46.1%) | (47.7%) | 12% |
|
| ROE | (86.9%) | (55.0%) | 10% |
|
| Liabilities to Assets | 39.7% | 29.4% | 30% |
|
| F-Score | 5 | 3 | 50% |
|
Viridian Therapeutics, Inc. did not pass any screens on 10/13/2026.
